Ad Header



The Pulse of the Pharmaceutical Industry

FDA declines to approve Pfizer biosimilar

Written by: | | Dated: Monday, April 23rd, 2018


FDA declines to approve Pfizer biosimilar of Roche’s cancer drug


(Reuters) – Pfizer Inc said on Monday U.S. regulators declined to approve the company’s biosimilar of Roche’s blockbuster treatment for breast cancer, Herceptin, and sought additional technical information.

The company said the requested information did not relate to safety or clinical data submitted in the application.

Herceptin and other complex medicines called biologics are made from living cells, making them difficult to copy with precision. Their similar versions are called biosimilars, instead of generics.

Herceptin, which generated sales of 7.01 billion Swiss francs ($7.18 billion) in 2017, is one of the world’s most successful antibody drugs and has been a mainstay of Roche profits for many years.

FDA in December approved Mylan’s biosimilar of Herceptin.

($1 = 0.9758 Swiss francs)


Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Anil D’Silva and Sriraj Kalluvila


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom